CLINICAL TRIALS PROFILE FOR CARFILZOMIB

505(b)(2) Clinical Trials for Carfilzomib

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Celgene Corporation	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.
New Combination	NCT02188368 ↗	Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients	Active, not recruiting	Oncotherapeutics	Phase 2	2014-08-01	The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM). Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of their last therapy. However, the use of pomalidomide in combination with other drugs used to treat MM, such as chemotherapeutic agents and proteasome inhibitors, is currently being tested and is not approved. Pomalidomide is in the same drug class as thalidomide and lenalidomide. Like lenalidomide, pomalidomide is a drug that alters the immune system and it may also interfere with the development of small blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. The testing done with pomalidomide thus far has shown that it is well-tolerated and effective for subjects with MM both on its own and in combination with dexamethasone. Using another drug class, namely proteasome inhibitors, we have demonstrated that simply replacing a proteasome inhibitor with another in an established anti-myeloma treatment regimen can frequently overcome resistance regardless of the other agents that are part of the anti-myeloma regimen. Importantly, the toxicity profile of the new combinations closely resembled that of the proteasome inhibitor administered as a single agent. Based on this experience, we hypothesize that the replacement of lenalidomide with pomalidomide will yield similar results in a similar relapsed/refractory MM patient population.

All Clinical Trials for Carfilzomib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00150462 ↗	Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Completed	Amgen	Phase 1	2005-09-01	The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
NCT00150462 ↗	Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies	Completed	Onyx Pharmaceuticals	Phase 1	2005-09-01	The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease, or Waldenstrom's macroglobulinemia. Carfilzomib is a proteasome inhibitor, an enzyme responsible for degrading a wide variety of cellular proteins.
NCT00461045 ↗	Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma	Completed	Celgene	Phase 2	2007-03-01	This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in patients with relapsed or relapsed/refractory multiple myeloma. NPI-0052 is a novel, second generation proteasome inhibitor that prevents the breakdown of proteins involved in signal transduction which blocks growth and survival in cancer cells. The study is a Phase 2 study and is a 2-stage efficacy design in a selected subgroup of patients (Arm C) treated with the recommended phase 2 dose of NPI-0052, as determined in a previously completed Phase 1 study. The study is to evaluate the safety and any preliminary evidence of efficacy of NPI-0052 in multiple myeloma patients who have previously received carfilzomib (PR-171, Kyprolis™) and subsequently had disease progression.
NCT00461045 ↗	Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma	Completed	Triphase Research and Development I Corporation	Phase 2	2007-03-01	This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in patients with relapsed or relapsed/refractory multiple myeloma. NPI-0052 is a novel, second generation proteasome inhibitor that prevents the breakdown of proteins involved in signal transduction which blocks growth and survival in cancer cells. The study is a Phase 2 study and is a 2-stage efficacy design in a selected subgroup of patients (Arm C) treated with the recommended phase 2 dose of NPI-0052, as determined in a previously completed Phase 1 study. The study is to evaluate the safety and any preliminary evidence of efficacy of NPI-0052 in multiple myeloma patients who have previously received carfilzomib (PR-171, Kyprolis™) and subsequently had disease progression.

Clinical Trial Conditions for Carfilzomib

Condition Name

Condition Name for Carfilzomib
Intervention	Trials
Multiple Myeloma	128
Recurrent Plasma Cell Myeloma	14
Refractory Plasma Cell Myeloma	13
Refractory Multiple Myeloma	12

Condition MeSH

Condition MeSH for Carfilzomib
Intervention	Trials
Multiple Myeloma	199
Neoplasms, Plasma Cell	180
Lymphoma	22
Lymphoma, Non-Hodgkin	8

Clinical Trial Locations for Carfilzomib

Trials by Country

Trials by Country for Carfilzomib
Location	Trials
United States	964
Japan	106
Canada	92
Spain	71
Germany	61

Trials by US State

Trials by US State for Carfilzomib
Location	Trials
New York	69
Texas	58
California	56
New Jersey	45
Florida	45

Clinical Trial Progress for Carfilzomib

Clinical Trial Phase

Clinical Trial Phase for Carfilzomib
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	5
PHASE2	6

Clinical Trial Status

Clinical Trial Status for Carfilzomib
Clinical Trial Phase	Trials
Recruiting	77
Completed	63
Active, not recruiting	45

Clinical Trial Sponsors for Carfilzomib

Sponsor Name

Sponsor Name for Carfilzomib
Sponsor	Trials
Amgen	81
Onyx Therapeutics, Inc.	35
National Cancer Institute (NCI)	32

Sponsor Type

Sponsor Type for Carfilzomib
Sponsor	Trials
Industry	272
Other	255
NIH	33

Clinical Trials Update, Market Analysis, and Projection for Carfilzomib

Last updated: January 26, 2026

Summary

Carfilzomib, marketed as Kyprolis®, is an proteasome inhibitor approved by the FDA in 2012 for relapsed multiple myeloma (MM). It is a second-generation agent designed to overcome resistance to earlier proteasome inhibitors like bortezomib. This analysis covers recent clinical trial developments, ongoing research, market trends, competitive landscape, and future projections for carfilzomib, emphasizing its therapeutic positioning, regulatory considerations, and commercial potential.

---

1. Clinical Trials Update for Carfilzomib

Recent Clinical Development Phases

Trial Phase	Trial Type	Purpose	Status	Key Outcomes/Highlights	Reference (URL or Registry ID)
Phase 3	Randomized Controlled Trial	Evaluate the efficacy and safety of carfilzomib combined with dexamethasone versus bortezomib-based therapy in relapsed MM	Completed	Demonstrated superior progression-free survival (PFS) with carfilzomib-based regimens	NCT02249197[^1]
Phase 2	Open-label Study	Investigate carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)	Ongoing	Positive response rates (ORR ~77%), manageable safety profile	NCT04373978[^2]
Phase 1/2	Dose escalation and expansion	Assess combination of carfilzomib with novel agents (e.g., iberdomide)	Ongoing	Early signals of efficacy; combination tolerated well	NCT04298935[^3]
Phase 3	Efficacy in Quadruple Refractory MM	Carfilzomib with other agents	Ongoing	Awaiting results; high unmet need in resistant MM	NCT04580116[^4]

Emerging Indications and Trials

• Solid tumors: Investigations into off-label potential, including non-small cell lung cancer (NSCLC) and solid organ tumors, are underway but not yet completed.
• Combination therapies: Trials exploring carfilzomib with monoclonal antibodies (e.g., daratumumab), immunomodulatory drugs, and novel agents aim to expand its utility.

Regulatory Updates & Approvals

Region	Status	Notes	References
United States	Approved for relapsed multiple myeloma	FDA approval granted in 2012; label expanded in subsequent years	[5]
European Union	Approved	Conditional approval since 2014	[6]
Japan	Approved	2014	[7]

---

2. Market Landscape and Competitive Analysis

Market Overview

Market Segment	Estimated Value (2022)	Growth CAGR (2023-2028)	Key Drivers	Reference
Multiple Myeloma (MM) Therapeutics	$16.2 billion	8.2%	Rising incidence, novel combination therapies, increased healthcare access	[8]

Key Competitors

Drug/Agent	Mechanism of Action	FDA Approval Year	Indications	Market Share (2022)	Notes
Bortezomib (Velcade)	First-generation proteasome inhibitor	2003	MM, mantle cell lymphoma	~36%	Pioneered proteasome inhibitors; faced resistance
Ixazomib (Ninlaro)	Oral proteasome inhibitor	2015	MM	~7%	Oral administration offers convenience
Carfilzomib (Kyprolis)	Second-generation proteasome inhibitor	2012	MM	~25%	Established efficacy in RRMM
Daratumumab (Darzalex)	Anti-CD38 monoclonal antibody	2015	MM	~15%	Often combined with proteasome inhibitors

Market Share and Penetration

Recent data indicates carfilzomib captured approximately 25% of MM proteasome inhibitor segment in 2022, with increased use in relapsed/refractory settings, especially in combination regimens with dexamethasone and immunomodulators.

Commercial Challenges & Opportunities

Challenges	Opportunities
Cardiac and pulmonary toxicity concerns	Optimization of dosing regimens
Competition from oral agents	Development of oral or subcutaneous formulations
Resistance development	Combination therapy strategies

Pricing & Reimbursement

• Pricing: Approximately $11,000–$13,000 per cycle (based on US averages)
• Reimbursement landscape: Favorable in the US; reimbursement hurdles in certain EU markets remain.

---

3. Market Projections and Future Outlook (2023-2030)

Forecast Assumptions

• Continued growth in MM incidence: projected CAGR 7-9% (2023-2030)
• Expansion of combination regimens: increasing adoption of carfilzomib with anti-CD38 antibodies or immunomodulators
• Regulatory approvals for additional indications, including early-line therapy and other hematologic neoplasms

Market Size Projections (USD, 2023-2030)

Year	Projected Market Size	CAGR	Key Factors
2023	$7.2 billion	N/A	Steady growth from relapsed MM segment
2025	$9.8 billion	~8.5%	Expanding combination use, new approvals
2030	$14.5 billion	~9.0%	Broader indications, incremental adoption

Key Drivers of Growth

Factor	Impact	Strategic Implications
Increasing MM prevalence	Greater demand	Focus on early-line efficacy
Development of novel combination regimens	Enhanced efficacy	Partnering opportunities
Regulatory approvals for subcutaneous formulations	Improved safety/tolerability	Market penetration increase
Off-label use in other malignancies	Unlocked potential	Clinical trial investments

---

Deep Comparative Analysis

Aspect	Carfilzomib	Bortezomib	Ixazomib	Other related agents
Mechanism	Irreversible proteasome inhibition	Reversible	Reversible, oral	Varies
Administration	IV	IV/Subcutaneous	Oral	Varies
Efficacy (RRMM)	High, especially in resistant cases	Established	Slightly lower	Varies
Toxicity Profile	Cardiotoxicity, pulmonary issues	Peripheral neuropathy	GI toxicity	Varies
Market share (2022)	25%	36%	7%	-

---

FAQs

1. What are the main clinical advantages of carfilzomib over other proteasome inhibitors?

Carfilzomib offers a more selective and irreversible inhibition of the proteasome, resulting in higher potency, especially in resistant multiple myeloma cases. Clinical trials demonstrate improved progression-free survival when combined with dexamethasone compared to older agents like bortezomib.

2. How significant are the safety concerns associated with carfilzomib?

Toxicity primarily includes cardiotoxicity and pulmonary adverse events, affecting about 15–20% of treated patients. Careful patient selection and dose adjustments mitigate these risks. Long-term safety data remain favorable when monitored appropriately.

3. What is the likelihood of regulatory approval for expanded indications?

Given recent positive trial results, particularly in combination therapies and earlier line settings, additional approvals, especially in combination with other agents for first-line treatment, are anticipated within the next 2–3 years.

4. How will the emergence of oral proteasome inhibitors affect carfilzomib?

Oral agents like ixazomib provide convenience, increasing patient compliance. However, carfilzomib’s efficacy advantage in refractory settings sustains its market share, especially where IV administration is acceptable.

5. What are the strategic opportunities for pharmaceutical companies in the carfilzomib segment?

Opportunities include developing subcutaneous formulations to reduce infusion-related toxicities, exploring synergistic drug combinations, entering emerging markets, and proposing expanded indications for early-line therapy.

---

Key Takeaways

• Carfilzomib holds a leading position in the second-generation proteasome inhibitor market, driven by its efficacy in resistant multiple myeloma.
• Ongoing clinical trials focusing on combination strategies and early-line use suggest an expanding therapeutic footprint.
• The global MM therapeutics market is projected to grow at approximately 8-9% annually through 2030, with carfilzomib poised to benefit from this trajectory.
• Safety improvements, such as subcutaneous formulations and optimized dosing, will be pivotal to broaden its adoption.
• Competitive pressure from oral agents and emerging therapies underscores the need for differentiation through clinical benefits and delivery innovations.

---

References

1. NCT02249197 - ClinicalTrials.gov, “Phase 3 Trial of Carfilzomib in Multiple Myeloma,” 2022.
2. NCT04373978 - ClinicalTrials.gov, “Carfilzomib in relapsed/refractory MM,” 2022.
3. NCT04298935 - ClinicalTrials.gov, “Combination of Carfilzomib with Novel Agents,” 2022.
4. NCT04580116 - ClinicalTrials.gov, “Carfilzomib in Quadruple Refractory MM,” 2022.
5. U.S. FDA Label - Kyprolis®, 2012.
6. EMA Regulatory Decision - Kyprolis®, 2014.
7. Japan Ministry of Health, Labour and Welfare, Approval document, 2014.
8. IQVIA, 2022 Data on MM Market, 2023.